At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 266 enrolled
Drug / intervention
bimatoprost 0.03% eye drops +1 moredrug
Likely dose
Bimatoprost 0.03% 1 drop nightly or travoprost 0.004% 1 drop nightly for 3 monthsAI-extracted
Key inclusion· 4
- ✓Glaucoma or ocular hypertension affecting both eyes
- ✓Currently treated with latanoprost 0.005% daily with inadequate intraocular pressure control
- ✓Best-corrected visual acuity of 20/100 or better in each eye
- ✓Visual field test within 6 months prior to enrollment
Key exclusion· 3
- ✕Secondary glaucoma
- ✕Active intraocular inflammation or macular edema
- ✕Intraocular or laser surgery within the past 3 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
In Brief
A Phase 4 clinical trial evaluating bimatoprost 0.03% eye drops and travoprost 0.004% eye drops for Glaucoma and Ocular Hypertension. Completed, enrolled 266 participants across 1 site.
Detailed Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedFeb 2007
Primary CompletionOct 2007
TodayJul 2026
First PostedFeb 26, 2007
Enrollment StartAug 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.3 years ago
Interventions
bimatoprost 0.03% eye dropsdrug
bimatoprost 0.03% 1 drop nightly for 3 months
travoprost 0.004% eye dropsdrug
travoprost 0.004% 1 drop nightly for 3 months